18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions

Secondary Malignant Neoplasm of Brain and Cerebral Meninges

Interventions

DRUG

18F-fluciclovine

A single dose of 18F-fluciclovine will be administered intravenously for PET/CT imaging. The standard 10 mCi dose will be used for this study.

DEVICE

PET/CT of the brain

Each subject will undergo 18F-fluciclovine PET/CT of the brain which will be performed ≤ 30 days from equivocal MRI brain

Trial Locations (1)

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors

lead

Case Comprehensive Cancer Center

OTHER

NCT03930173 - 18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis | Biotech Hunter | Biotech Hunter